array(40) {
  [0]=>
  string(4) "5533"
  ["article_id"]=>
  string(4) "5533"
  [1]=>
  string(80) "Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial"
  ["article_title"]=>
  string(80) "Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial"
  [2]=>
  string(150) "PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condi"
  ["short_description"]=>
  string(150) "PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condi"
  [3]=>
  string(582) "
PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condition. The late-stage trial enrolled 500 patients 
&#nl
The post Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(582) "
PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condition. The late-stage trial enrolled 500 patients 
&#nl
The post Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/halozyme-pegph20-halo-301-trial/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/halozyme-pegph20-halo-301-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5534"
  ["article_id"]=>
  string(4) "5534"
  [1]=>
  string(88) "RedHill Biopharma secures FDA approval for Talicia to treat H pylori infection in adults"
  ["article_title"]=>
  string(88) "RedHill Biopharma secures FDA approval for Talicia to treat H pylori infection in adults"
  [2]=>
  string(150) "RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage"
  ["short_description"]=>
  string(150) "RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage"
  [3]=>
  string(570) "
RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage. RedHill Biopharma chief 
&#nl
The post RedHill Biopharma secures FDA approval for Talicia to treat H pylori infection in adults appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(570) "
RedHill said that its Talicia has been indicated for oral administration in the form of delayed-release capsules in 10mg, or 250mg or in 12.5mg dosage. RedHill Biopharma chief 
&#nl
The post RedHill Biopharma secures FDA approval for Talicia to treat H pylori infection in adults appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/redhill-talicia-h-pylori-infection/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/redhill-talicia-h-pylori-infection/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5535"
  ["article_id"]=>
  string(4) "5535"
  [1]=>
  string(97) "BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva"
  ["article_title"]=>
  string(97) "BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva"
  [2]=>
  string(150) "The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results f"
  ["short_description"]=>
  string(150) "The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results f"
  [3]=>
  string(633) "
The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results from the trial in 
&#nl
The post BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(633) "
The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. The company expects to report the results from the trial in 
&#nl
The post BioCryst begins phase 1 trial with BCX9250 for treatment of fibrodysplasia ossificans progressiva appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/biocryst-begins-phase-1-trial-with-bcx9250-for-treatment-of-fibrodysplasia-ossificans-progressiva/"
  ["blog_url"]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/biocryst-begins-phase-1-trial-with-bcx9250-for-treatment-of-fibrodysplasia-ossificans-progressiva/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5536"
  ["article_id"]=>
  string(4) "5536"
  [1]=>
  string(78) "Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA"
  ["article_title"]=>
  string(78) "Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA"
  [2]=>
  string(150) "Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in"
  ["short_description"]=>
  string(150) "Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in"
  [3]=>
  string(569) "
Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in the head-to-head late-stage trial. As 
&#nl
The post Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(569) "
Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in the head-to-head late-stage trial. As 
&#nl
The post Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/novartis-cosentyx-exceed-trial/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/novartis-cosentyx-exceed-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5537"
  ["article_id"]=>
  string(4) "5537"
  [1]=>
  string(91) "Amgen enters into strategic collaboration with BeiGene to expand oncology presence in China"
  ["article_title"]=>
  string(91) "Amgen enters into strategic collaboration with BeiGene to expand oncology presence in China"
  [2]=>
  string(150) "BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person c"
  ["short_description"]=>
  string(150) "BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person c"
  [3]=>
  string(691) "
BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. “This 
&#nl
The post Amgen enters into strategic collaboration with BeiGene to expand oncology presence in China appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(691) "
BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. “This 
&#nl
The post Amgen enters into strategic collaboration with BeiGene to expand oncology presence in China appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(144) "https://www.pharmaceutical-business-review.com/news/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/"
  ["blog_url"]=>
  string(144) "https://www.pharmaceutical-business-review.com/news/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5538"
  ["article_id"]=>
  string(4) "5538"
  [1]=>
  string(104) "Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute"
  ["article_title"]=>
  string(104) "Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute"
  [2]=>
  string(150) "The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize glob"
  ["short_description"]=>
  string(150) "The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize glob"
  [3]=>
  string(681) "
The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo’s 
&#nl
The post Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(681) "
The study is the first in the strategic oncology partnership announced between Daiichi Sankyo and Sarah Cannon, designed to expedite and optimize global clinical development of Daiichi Sankyo’s 
&#nl
The post Daiichi Sankyo initiates clinical trial of DS-7300 in collaboration with Sarah Cannon Research Institute appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/daiichi-sankyo-initiates-clinical-trial-of-ds-7300-in-collaboration-with-sarah-cannon-research-institute/"
  ["blog_url"]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/daiichi-sankyo-initiates-clinical-trial-of-ds-7300-in-collaboration-with-sarah-cannon-research-institute/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5539"
  ["article_id"]=>
  string(4) "5539"
  [1]=>
  string(109) "Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology"
  ["article_title"]=>
  string(109) "Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology"
  [2]=>
  string(157) "This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegratin"
  ["short_description"]=>
  string(157) "This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegratin"
  [3]=>
  string(713) "
This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology 
&#nl
The post Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(713) "
This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology 
&#nl
The post Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(162) "https://www.pharmaceutical-business-review.com/news/cycle-pharmaceuticals-and-catalent-partner-to-develop-treatments-for-rare-diseases-using-zydis-odt-technology/"
  ["blog_url"]=>
  string(162) "https://www.pharmaceutical-business-review.com/news/cycle-pharmaceuticals-and-catalent-partner-to-develop-treatments-for-rare-diseases-using-zydis-odt-technology/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-06 14:38:14"
  ["create_at"]=>
  string(19) "2019-11-06 14:38:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5697"
  ["article_id"]=>
  string(4) "5697"
  [1]=>
  string(115) "Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design"
  ["article_title"]=>
  string(115) "Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design"
  [2]=>
  string(160) "The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building bl"
  ["short_description"]=>
  string(160) "The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building bl"
  [3]=>
  string(722) "
The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The 
&#nl
The post Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(722) "
The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The 
&#nl
The post Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(168) "https://www.pharmaceutical-business-review.com/news/cyclica-collaborates-with-enamine-to-use-real-technology-in-its-ligand-design-platform-for-ai-augmented-drug-design/"
  ["blog_url"]=>
  string(168) "https://www.pharmaceutical-business-review.com/news/cyclica-collaborates-with-enamine-to-use-real-technology-in-its-ligand-design-platform-for-ai-augmented-drug-design/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-07 11:07:43"
  ["create_at"]=>
  string(19) "2019-11-07 11:07:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5698"
  ["article_id"]=>
  string(4) "5698"
  [1]=>
  string(80) "A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics"
  ["article_title"]=>
  string(80) "A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics"
  [2]=>
  string(150) "The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research "
  ["short_description"]=>
  string(150) "The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research "
  [3]=>
  string(616) "
The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research – targeted killing of tumor 
&#nl
The post A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(616) "
The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research – targeted killing of tumor 
&#nl
The post A2 Biotherapeutics emerges from Stealth Mode to develop tumour cell therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(133) "https://www.pharmaceutical-business-review.com/news/a2-biotherapeutics-emerges-from-stealth-mode-to-develop-tumour-cell-therapeutics/"
  ["blog_url"]=>
  string(133) "https://www.pharmaceutical-business-review.com/news/a2-biotherapeutics-emerges-from-stealth-mode-to-develop-tumour-cell-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-07 11:07:43"
  ["create_at"]=>
  string(19) "2019-11-07 11:07:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5699"
  ["article_id"]=>
  string(4) "5699"
  [1]=>
  string(66) "Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo"
  ["article_title"]=>
  string(66) "Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo"
  [2]=>
  string(150) "Ziextenzo, like its reference drug pegfilgrastim, has been indicated to reduce the chances of infection caused by low white blood cell count with a fe"
  ["short_description"]=>
  string(150) "Ziextenzo, like its reference drug pegfilgrastim, has been indicated to reduce the chances of infection caused by low white blood cell count with a fe"
  [3]=>
  string(554) "
Ziextenzo, like its reference drug pegfilgrastim, has been indicated to reduce the chances of infection caused by low white blood cell count with a fever – a condition 
&#nl
The post Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(554) "
Ziextenzo, like its reference drug pegfilgrastim, has been indicated to reduce the chances of infection caused by low white blood cell count with a fever – a condition 
&#nl
The post Sandoz secures FDA approval for pegfilgrastim biosimilar Ziextenzo appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(94) "https://www.pharmaceutical-business-review.com/news/sandoz-pegfilgrastim-biosimilar-ziextenzo/"
  ["blog_url"]=>
  string(94) "https://www.pharmaceutical-business-review.com/news/sandoz-pegfilgrastim-biosimilar-ziextenzo/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-07 11:07:43"
  ["create_at"]=>
  string(19) "2019-11-07 11:07:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5700"
  ["article_id"]=>
  string(4) "5700"
  [1]=>
  string(76) "Japan’s Takeda opens dengue vaccine manufacturing facility in Germany"
  ["article_title"]=>
  string(76) "Japan’s Takeda opens dengue vaccine manufacturing facility in Germany"
  [2]=>
  string(150) "The company will use the new manufacturing plant for formulation, fill, finish and secondary packaging of the TAK-003 tetravalent dengue vaccine candi"
  ["short_description"]=>
  string(150) "The company will use the new manufacturing plant for formulation, fill, finish and secondary packaging of the TAK-003 tetravalent dengue vaccine candi"
  [3]=>
  string(623) "
The company will use the new manufacturing plant for formulation, fill, finish and secondary packaging of the TAK-003 tetravalent dengue vaccine candidate. Takeda started the initial construction activities 
&#nl
The post Japan’s Takeda opens dengue vaccine manufacturing facility in Germany appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(623) "
The company will use the new manufacturing plant for formulation, fill, finish and secondary packaging of the TAK-003 tetravalent dengue vaccine candidate. Takeda started the initial construction activities 
&#nl
The post Japan’s Takeda opens dengue vaccine manufacturing facility in Germany appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(121) "https://www.pharmaceutical-business-review.com/news/japans-takeda-opens-dengue-vaccine-manufacturing-facility-in-germany/"
  ["blog_url"]=>
  string(121) "https://www.pharmaceutical-business-review.com/news/japans-takeda-opens-dengue-vaccine-manufacturing-facility-in-germany/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-07 11:07:43"
  ["create_at"]=>
  string(19) "2019-11-07 11:07:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5788"
  ["article_id"]=>
  string(4) "5788"
  [1]=>
  string(97) "Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates"
  ["article_title"]=>
  string(97) "Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates"
  [2]=>
  string(150) "SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing "
  ["short_description"]=>
  string(150) "SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing "
  [3]=>
  string(689) "
SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEAiii (aflibercept), is in pre-clinical development. In addition, the 
&#nl
The post Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(689) "
SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEAiii (aflibercept), is in pre-clinical development. In addition, the 
&#nl
The post Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/samsung-bioepis-enters-into-commercialisation-agreement-for-next-generation-biosimilar-candidates/"
  ["blog_url"]=>
  string(150) "https://www.pharmaceutical-business-review.com/news/samsung-bioepis-enters-into-commercialisation-agreement-for-next-generation-biosimilar-candidates/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-08 13:13:54"
  ["create_at"]=>
  string(19) "2019-11-08 13:13:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}